Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial - Supplementary Materials

Supplementary Materials for the manuscript titled 'Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial'.

Includes demographics and baseline characteristics for the patient groups included in the manuscript (Supplementary Table 1), an overview of the efficacy outcomes included in the manuscript using different imputation methods for missing data (Supplementary Table 2), a patient disposition flow chart (Supplementary Figure 1), PASI ≤2 and PASI 90 response rates over Weeks 0–96 (Supplementary Figure 2 and Supplementary Figure 3), and supplementary methods describing the adjudication of certain treatment-emergent adverse events in this study (Adjudication of TEAEs).